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Background: Patients do not always receive guideline-adherent therapy, yet little is known about the underlying
causes on the patients’ side. We quantified non-guideline-adherent treatment of chronic diseases (diabetes mellitus,
hypertension, cardiovascular disease, heart failure, atrial fibrillation) in primary care and analysed the causes from
the physician’s as well as the patient’s view.
Methods: With the intention to analyze the frequency and causes of non-guideline-adherent treatment of patients
with chronic diseases, we drew a random sample of 124 general practitioners (GP) in Salzburg, Austria, of which 58
(46.8%) participated. In the participating GP surgeries, we consecutively recruited 501 patients with at least one of
the target-diseases and checked the guideline conformity of treatment using 9 quality indicators. We then
interviewed the patients as well as the general practitioners regarding factors affecting deviation from guideline
recommendations.
Results: Of the 501 patients, a total of 1224 quality indicators could be analysed. Non-adherence to guideline
recommendations were present in 16.8% (n = 205, 95% CI 14.7 to 18.8%) of all quality indicators. In 61.5% of these
cases (n = 126, 95% CI 53.0 to 70.0%) the treatment was wrongly judged as not recommended by the physicians. In
10.2% (n = 21, 95% CI 0 to 23.2%) physicians attributed non-adherence to patient’s non-compliance, and in 10.7%
(n = 22, 95% CI 0 to 23.7%) to an adverse drug event, whereas only 5.4% (n = 11, 95% CI 0 to 18.7%) of non-
adherence was related to an adverse drug event reported by the patients. Patients were unaware regarding the
reason for non-adherent therapy in 64.4% (n = 132, 95% CI 56.2 to 72.6%) of the quality indicators. In 20.0% (n = 41,
95% CI 7.8 to 32.2%) patients regarded a drug as not needed.
Conclusions: Guideline adherence in chronic care was relatively good in our study sample, but still leaving room
for improvement. Physicians’ lack of knowledge and patients’ lack of awareness account for about 70% of
non-adherence, indicating the necessity to improve physician education, and patient involvement. In about 30%
of the quality indicators not fulfilled, non-adherence is due to other reasons like adverse drug events or patients
not willing to take a recommended drug.
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To decrease the burden of chronic diseases, treatment
guidelines have been developed based on current best evi-
dence from large clinical trials. In Austria, the EbM-
Guidelines [1] are most widely used. However, we know
from various studies that guidelines are not always applied
and followed [2-5]. The barriers to guideline-adherence
have been studied quite extensively concerning the physi-
cian’s point of view, mainly in qualitative [6-10], but also
in quantitative studies. A systematic review of studies
addressing physicians’ barriers to guideline adherence,
identified physicians’ lack of awareness of a guideline’s
existence and lack of familiarity with the guideline as the
leading causes of deviation from recommended therapy
[11]. Thus ample data exist on the epidemiology of guide-
line adherence as well as physicians’ barriers to guideline
implementation, leading to the assumption that physicians
are generally responsible for non-adherence. Based on
this assumption, the quality and outcomes framework
has been designed in the UK and proven to enhance
guideline-adherence substantially [12].
Besides non-adherence due to lack of awareness and
lack of familiarity, there may be other reasons for not pre-
scribing a drug which are related to the individual patient,
his values, and preferences. Much less is known about
patient-related causes of non-adherence to the guidelines.
A recent study identified patient ability and patient prefer-
ences as potential barriers, based on a survey of GP per-
ceptions [13], but we are not told how patients themselves
perceive these barriers, and we could not identify a single
study looking at both patient- and physician-related causes
of non-adherence at the same time.
We therefore conducted a cross-sectional study in the
primary care setting to detect and quantify non-guideline-
adherent treatment of chronic diseases, and to quantita-
tively analyse the causes of non-adherence from the
physician’s as well as the patient’s point of view. Since
cardiovascular disease represents the major cause of
morbidity and death [14], and demographic changes may
lead to a further rise in prevalence, we decided to concen-
trate particularly on these diseases (cardiovascular disease,
heart failure, atrial fibrillation) and the most important
risk factors (diabetes mellitus type 2 and hypertension).
Methods
We obtained a complete list of all 200 general practitioners
(GPs) under contract with statutory public health insur-
ance in four districts (Salzburg city, Pongau, Tennengau,
Flachgau) of the province of Salzburg, Austria. GPs were
randomly listed by an electronic randomisation process.
Following this order, physicians were asked to participate
in the study to obtain a random sample of 58 GPs, corre-
sponding to the study duration of three months (58 con-
secutive working days from January to April 2011). Eachsurgery was audited for one day by the principal researcher
(JF). On that day, all consecutive patients with at least one
of the target diseases or risk factors (arterial hypertension,
diabetes mellitus type 2, heart failure, atrial fibrillation, car-
diovascular disease) were asked to participate in the study.
In Austria, patients can freely choose their GP and usually
visit the surgery without arranging appointments. Thus the
patient sample represents a random consecutive selection.
After signing informed consent, the patients were assessed
via a structured case report form (CRF). We collected
demographic data, smoking status, patient’s diagnoses
regarding chronic diseases, medication and medical data
(from the surgery’s patient health record). A detailed
description of patient data is presented in Table 1.
We used 9 quality indicators (QI) based on the EbM-
guidelines most commonly applied in Austria [1] to de-
termine guideline-adherence regarding the treatment of
the target-diseases mentioned above. The QIs are de-
scribed in detail in Table 2.
Patients with hypertension were considered to be inad-
equately treated if they did not reach the target of 140 -
mmHg in multiple measurements or 24-hour-monitoring,
or if a single measurement was above 160 mmHg.
Since we only evaluated cardiovascular diseases as men-
tioned, it was not possible to evaluate all contraindications
for each particular drug. As we collected patients’ creatin-
ine values, it was possible to calculate the GFR and to
define a GFR lower than 60 ml/min as an exclusion criter-
ion for metformin therapy. All other more or less weak
contraindications, e.g. COPD as a contraindication for
β-blockers in the treatment of patients after myocardial
infarction, were not specifically obtained and were only
recorded as non-specified “contraindications” in our clin-
ical report form (CRF; see Table 3).
We then interviewed the patient and the physician in-
dependently about underlying reasons for non-adherent
treatment, using a structured CRF. The reasons given by
patients and physicians are presented in Table 3. The
category “other” was offered but it was possible to trans-
fer each answer to one of the other offered causes. All
data were pseudonymised and recorded in pre-specified
case report forms and then transferred to IBMW SPSSW
Statistics19.0 for further analysis.
The study was carried out in compliance with the Dec-
laration of Helsinki and with Austrian data protection le-
gislation. Ethics approval has been obtained from the
ethics committee of the federal state of Salzburg, Austria.
Results
We had to randomly select 124 of the 200 GPs eligible
to obtain a sample of 58 GPs willing to participate (re-
sponse rate 46.8%). In these 58 GP surgeries 526 con-
secutive patients were invited to participate in the study.
501 of these patients (95.3%) gave informed consent and
Table 1 Data collected via case report form (CRF)






Chronic diseases Diabetes mellitus type 2 ± micro- or macro-vascular complications
Arterial hypertension
Atrial fibrillation
Heart failure (including NYHA-stage)
Cardiovascular diseases Myocardial infarction, aortocoronary bypass or stenting, angina
pectoris and coronary stenosis* , peripheral arterial occlusive
disease, peripheral arterial thromboembolism
Cerebrovascular diseases Stroke, transitory ischemic attack, carotid endarterectomy
or stenting
Medication Oral antidiabetics Metformin
Antihypertensive drugs Inhibitors of the renin-angiotensin-aldosterone system (RAAS),
diuretics (thiazides, furosemide) calcium channel blockers,
beta-blockers
Platelet aggregation Inhibitors Acetylsalicylic acid, clopidogrel, prasugrel
Anticoagulants Vitamine-K-antagonists
Lipid lowering therapy Statins
Medical data (via patient’s
health records)




International normalized ratio In case of oral anticoagulation
Total serum cholesterol, LDL and HDL levels
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mean of 8.6 ± 5.3 (SD) patients per surgery. These pa-
tients had a total number of 922 target diseases with a
total number of 1224 QIs analysed (three QIs for heart
failure, three QIs for cardiovascular disease, and one QITable 2 List of quality indicators (QIs)
QI Medication
1 inhibitors of the renin-angiotensin-aldosterone system (RAAS; ACE-I
or ARB or Renin-Inhibitors [RI]), calcium channel blockers, β-blockers







8 Platelet aggregation inhibitor
9 β-blockerfor each of the other diseases). Descriptive data of all pa-
tients are depicted in Table 4.
The prevalence of the targeted chronic diseases within
our cohort and the percentage of patients not treated
according to the guidelines using the QIs defined aboveThreshold or indication
Arterial hypertension with BP above target (systolic BP >140 mmHg
in multiple or 24 h-measurements or >160 mmHg in single
measurement)
Diabetes mellitus type 2 (HbA1c >53 mmol/mol (7%))
Chronic heart failure (any stage)
Chronic heart failure (any stage)
Chronic heart failure, NYHA-stage III or IV
Atrial fibrillation
Any cardiovascular disease (coronary heart disease, cerebrovascular
disease, peripheral vascular disease)
Any cardiovascular disease
History of myocardial infarction
Table 3 Possible causes of non-adherence to the guidelines evaluated and transferral for analysis
Patient answer Transferred to Physician answer Transferred to
I do not know I do not know I do not know Falsely not indicated GP
I do not need it I do not need it Not indicated
I do not want it I do not want it Noncompliance Noncompliance
Avoidance of polypharmacy Avoidance of polypharmacy
Specialist did not prescribe it Falsely not indicated s/h*
I do not take it any more Adverse drug event Contraindication Contraindication
Falsely discontinued† Patient does not take it anymore Adverse drug event
Falsely discontinued†
(or one of the above) (or one of the above)
Other Allocation to one of the above Other Allocation to one of the above
* Falsely not indicated specialist / hospital (when a certain therapy was not initiated or recommended by specialists or physicians in the hospital, and the GP
adhered to this recommendation even though in fact there was an indication for the drug).
† Defined as a stop of treatment triggered by the physician despite guidelines recommending a continuation of the therapy (e.g. discontinuation of statin therapy
after reaching target values for LDL-cholesterol which then rose above target again).
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least one QI was not fulfilled. Overall, guideline adher-
ence was not given in 16.8% (95% CI 14.7 to 18.8%) of
all QIs. The distribution of possible causes of non-
adherent therapy is shown in Figure 1.
We performed a detailed analysis of underlying causes
for non-guideline-adherent treatment referring to each
target diagnosis and QI. The results of this analysis are
presented in Table 6.
Arterial hypertension was present in 424 patients
(84.6%). 76 patients (17.9%) had blood pressure measure-
ments above target (QI 1). A combination of up to four
antihypertensive drugs is recommended to reach optimal
blood pressure levels. Adequate combination therapy of
four antihypertensive drugs was prescribed in only 7 of
the patients with blood pressure above target (9.2%). The
causes of not fulfilling QI 1 in the remaining 69 patients
(90.8%) are listed in Table 6. Nineteen (27.5% of all) of
them were treated with a three-drug combination.
The study cohort included 174 patients with diabetes
mellitus type 2, of whom 64 (36.8% of all) did not re-
ceive metformin (QI 2). Thirty-two had a contraindica-
tion for metformin (glomerular filtration rate [GFR]
</=60 ml/min, using the Cockroft-Gault-formula). WeTable 4 Descriptive data of all patients (mean ± standard
deviation)
Descriptive data of all patients
Male total n 251 (50.1%)
Male smokers (%) 15.1
Female total n 250 (49.9%)
Female smokers (%) 9.6
Age (years ± SD) 69.5 ± 10.9
BMI (kg/m2 ± SD) 28.1 ± 4.8could not obtain a creatinine value for two of the pa-
tients. Nineteen of the remaining 30 patients had an
HbA1c value of less than 53 mmol/mol (7%), and for
three patients, we could not obtain an HbA1c value. All
in all, QI 2 was not fulfilled in only eight (4.6%) of all pa-
tients with diabetes mellitus type 2. The causes of devi-
ation from the guideline are listed in Table 6.
We found 41 patients with heart failure in our cohort,
15 (36.6% of all) did not receive any β-blocker (QI 3) and
8 (19.5% of all) were not treated with an RAAS-inhibitor
(QI 4), as would have been recommended. Seven (17.1%
of all) patients had a NYHA stage of III or more. The
NYHA stage was not definable in 3 patients, so QI 5 was
not fulfilled only in 4 patients (9.8% of all). The causes for
guideline deviation are listed in Table 6.
Atrial fibrillation was present in 106 patients, of whom
15 (14.0% of all) were not treated with oral anticoagu-
lants as defined in QI 6. The reasons for non-adherence
are presented in Table 6.
The diagnosis of any cardiovascular disease was present
in 177 patients. Fifty-three (29.9%) patients were not pre-
scribed any statin (QI 7). Two of them were treated with a
fibrate only, and one with ezetimib only. The reasons for
not receiving a statin or any lipid-lowering treatment as
defined in QI 7 are listed in Table 6.
Furthermore, 53 (29.9%) of the patients with cardio-
vascular disease did not take platelet aggregation inhibi-
tors (acetylsalicylic acid or clopidogrel or prasugrel) in
accordance with QI 8. As a meta-analysis of randomised
trials showed that the combination of platelet aggrega-
tion inhibitors and oral anticoagulants in patients with
atrial fibrillation does not have any additive benefit but
carries a higher risk for bleeding [15], we considered oral
anticoagulants an acceptable reason to discontinue
antiplatelet-therapy. This was the case in 41 patients, so
only 12 (6.8%) were not treated as recommended by the
Table 5 Diagnoses with numbers of QIs and QIs revealing non-adherence to the guidelines
Diagnosis n of cases with diagnosis
(number of QIs)
n of QIs revealing
non-adherent treatment
% QIs revealing non-adherent
treatment (95% CI)
Arterial hypertension 424 (424) 69 16.3 (12.8-19.9)
Diabetes mellitus type 2 174 (174) 8 4.6 (1.5-7.7)
Heart failure 41 (89) 27 30.3 (20.8-39.9)
β-Blocker 41 (41) 15 36.6 (21.8-51.3)
RAAS-I 41 (41) 8 19.5 (7.4-31.6)
Aldo-A in NYHA III/IV 7 (7) 4 57.1 (20.5-93.8)
Atrial fibrillation 106 (106) 15 14.2 (7.5-20.8)
Cardiovascular disease 177 (431) 86 20.0 (16.2-23.7)
Statin 177 (177) 53 29.9 (23.2-36.7)
Platelet aggregation inhibitors 177 (177) 12 6.8 (3.1-10.5)
β-blocker after myocardial infarction 77 (77) 21 27.3 (17.3-37.2)
Total* 922 (1224) 205 16.8 (14.7-18.8)
* The number of diagnoses exceeds the number of patients as many subjects had more than one of the target diagnoses.
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guidelines are listed in Table 6.
A history of myocardial infarction was present in 77 of
the 177 patients with cardiovascular disease, and 21
(27.3% of all patients with myocardial infarction) of
them were not on β-blocking treatment as defined in QI
9. The causes for non-adherence are listed in Table 6.Figure 1 Causes of deviations from the guidelines. Percentages are pe
discontinued” is defined as a stop of treatment triggered by the physician
discontinuation of statin therapy after reaching target values for LDL-chole
signifies that the GP never started therapy due to e.g. a knowledge gap an
hospital (s/h)” signifies that a certain therapy was not initiated or recomme
to this recommendation when in fact there was an indication for the drugDiscussion
We found obvious deficits in care regarding guideline ad-
herent drug therapy for hypertension, diabetes mellitus
type two, heart failure, atrial fibrillation and secondary
prevention in cardiovascular diseases. About a sixth of all
quality indicators in our study were not fulfilled according
to current guideline recommendations. In more than halfrcent of all Quality Indicators analyzed. Patient’s view: “Falsely
despite guidelines recommending a continuation of the therapy (e.g.
sterol). Physician’s view: “Falsely not indicated general practitioner (GP)”
d the drug in fact was indicated. “Falsely not indicated specialist /
nded by specialists or physicians in the hospital and the GP adhered
.
Table 6 Causes of deviation from guidelines for every drug and diagnosis in %
Causes of deviation from guidelines from patient’s view
n 69 8 15 8 4 15 53 12 21
Reason (in %) Anti-HT Metformin HF: βB HF: RAAS-I HF: AldoA AF: OAK CVD: statin CVD: antipltlt MCI: βB
I don’t know 91.3 50.0 60.0 62.5 75.0 66.7 30.2 50.0 76.2
I don’t need it 2.9 25.0 26.7 37.5 25.0 45.3 25.0 9.5
I don’t want it 12.5 13.3 7.5
Adverse drug event 4.3 13.3 6.7 7.5 4.8
Falsely discontinued 1.4 12.5 13.3 9.4 25.0 9.5
Causes of deviation from guidelines from physician’s view
n 69 8 15 8 4 15 53 12 21
Reason (in %) Anti-HT Metformin HF: βB HF: RAAS-I HF: AldoA AF: OAK CVD: statin CVD: PAI MCI: βB
Falsely not indicated GP 78.3 37.5 80.0 62.5 50.0 33.3 56.6 33.3 52.4
Falsely not indicated s/h 8.7 12.5 6.7 25.0 25.0 6.7 7.5 8.3 23.8
Noncompliance 2.9 25.0 20.0 17.0 25.0 9.5
Adverse drug event 8.7 25.0 6.7 12.5 25.0 6.7 11.3 25.0 4.8
Falsely discontinued 1.4 6.7 6.7 3.8
Contraindication 26.7 8.3 9.5
Avoidance of polypharmacy 3.8
Summation does not add up to 100% due to rounding error.
Anti-HT: antihypertensive medication (RAAS-inhibitor or thiazide or calcium channel blocker or β-blocker).
Metformin: metformin in diabetes mellitus type 2 patients.
HF = heart failure.
βB: beta adrenoceptor blocker.
RAAS-I: inhibitor of the renin-angiotensin-aldosterone system.
AldoA: aldosterone antagonist.
AF = atrial fibrillation.
OAK: oral anticoagulation.
CVD = cardiovascular disease.
PAI: platelet aggregation inhibitor (acetylsalicylic acid or clopidogrel/prasugrel).
MCI = myocardial infarction.
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they were not prescribed a particular drug, thus making
us look at the physician as the one responsible for non-
adherence. The most frequent reason for physicians to de-
viate from guideline recommendations was that they
falsely assumed that a certain prescription was not indi-
cated or necessary.
There are several possible explanations for the fact that
the treatment of patients is not always consistent with evi-
dence based recommendations. According to our study, the
most important cause appears to be the physician not pro-
viding a particular treatment. This may be due to physi-
cians’ lack of awareness regarding the existence of a
guideline, or lack of familiarity with a guideline, as has been
shown by Cabana et al. [11]. However, non-adherence may
also be caused by a deliberate decision to counteract the
guideline with which the physician may not agree, in gen-
eral or for a particular patient.
Even though the GP appears to be the main cause of
non-adherence to the guidelines, our study clearly shows
that other reasons are involved in at least one third of all
quality indicators.Of the non-GP-related causes, adverse drug events
and non-compliance appear to be the most important.
In chronic care, GPs are confronted with the problem
that they have to keep the patient compliant over a long
period of time, and that any drug treatment has to
match up to other health goals and is influenced by psy-
chosocial problems [16]. Chapman and co-authors found
a sharp decline in drug-adherence to lipid and blood
pressure lowering drugs to only 36% within one year,
with the greatest drop occurring in the first three
months [17]. The factors determining compliance are
manifold: Health education appears to play a crucial
role, but other patient specific factors like race, ethnicity,
or education are also important [18]. Sometimes patients
do not seem to be aware of their illness, or they accept
their chronic disease symptoms as normal, e.g. as a re-
sult of ageing. Thus, more than half of the patients with
heart failure reported their health to be good even
though nearly half of them could not walk a quarter of a
mile [5]. Another problem may be that many drug ef-
fects in cardiovascular prevention are hardly noticeable
to the patient so that the importance of the medication
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actions certainly also play a role in non-adherence to
recommended treatments. Moreover, insufficient com-
munication including incomplete patient’s history taking,
conflicting information, neglected disagreements, or a
disturbed relationship between the patient and the phys-
ician may cause non-adherence or non-compliance [19].
The fact that about two thirds of the patients did not
know why they do not receive a recommended drug
points out a significant information deficit. While we
would not expect all patients to wish to be informed
about treatment options, there appears to exist sufficient
evidence that most patients would prefer to be involved
in evidence based treatment decisions [20]. From our
study we cannot distinguish whether the information
deficit is due to a lack of communication between phys-
ician and patient, or to the patient not wanting to be in-
volved. Looking at one of the leading models for shared
decision making it takes both the physician’s willingness
to share information as well as the patient’s desire to be
informed [21], and we conclude from our study that it
seems unlikely that about two thirds of the patients do
not want to know about guideline-adherent, evidence-
based treatment choices.
About 20% of the patients in our study stated that they
do not need a drug they should in fact receive. This might
reflect certain knowledge deficits regarding present dis-
eases or risk factors.
Although our study reveals important insights regard-
ing the causes of non-adherence to guideline recommen-
dations, some limitations have to be considered. A
major weakness of our study is that the sample size is
fairly small. This especially limits the explanatory power
of the detailed analysis of single diseases, and even the
power of the combined data presented in Figure 1 can-
not be considered sufficient due to large confidence in-
tervals reaching zero on the left side.
Even though we chose a random sample of physicians,
our study may be biased by a response rate of only 50%
on the physician level. On the other hand, this response
rate is quite usual in studies involving primary care phy-
sicians. The systematic review of Cabana et al. reports a
median response rate of 54.5% for studies investigating
physicians’ lack of awareness as one of the barriers to
guideline adherence [11].
It may be assumed that rather motivated physicians
who already provide higher quality service to their pa-
tients are more likely to participate in a study of quality
analysis. But as our main goal in this study was not to
quantitatively analyse non-adherence, but rather differ-
entiate the possible reasons for non-adherence, we be-
lieve our data to be quite representative.
We visited each general practitioner only one day and
included only patients that consulted their doctor at thattime. This may bias our results as well, as one may as-
sume that less compliant patients tend to visit their
physician only at rare intervals. We tried to overcome
this problem by also including patients coming to the
surgery only to pick up a prescription.
We used a narrow set of only process quality indica-
tors to judge guideline adherence in drug therapy. This
may also be considered a weakness of our study. In dia-
betes mellitus type 2, for instance, it has been demon-
strated that there is insufficient evidence for many
widely used quality indicators regarding their predictive
power for clinically relevant outcomes [22]. This appears
to be a general problem of using quality indicators, and
is not specific to our study.
Last not least our structured interview technique
could only obtain categorical data on possible reasons
for non-adherence to evidence based guidelines. An in-
depth qualitative analysis of individual patients’ reasons
for not taking a drug or physicians’ reasons for not pre-
scribing it would be highly desirable and warrants fur-
ther research.
The strengths of our study are that we examined a
representative sample of consecutive patients from both
rural and urban areas, and we included all major dis-
eases affecting the cardiovascular system. So far very lit-
tle is known about the causes of non-adherence to
guideline recommended therapy on the patient’s side,
and thus this study provides data inspiring further re-
search to improve guideline-adherence in chronic care.
Conclusion
Overall, about 15% of all QI-cases examined in this study
were not treated according to the guidelines, and in 72% of
these a physician, either GP or specialist, judged a drug
falsely as not guideline recommended. In about the same
proportion of cases, the patients stated that they did not
know why they did not receive a drug recommended by the
guidelines, indicating information deficits on the patient’s
side. Lack of awareness, lack of knowledge, overlooking
values above target, or lack of communication, are possible
underlying causes. On the other hand, about 30% of the
QIs not fulfilled are due to various other reasons.
Our study points out that the improvement of guideline
adherent care is far more than getting physicians to follow
the guidelines. Patient information, patient involvement
and the physician’s willingness to inform and involve the
patient are just as important. Finally, our study makes
clear that 100% guideline-adherent care cannot be
achieved due to e.g. adverse drug reactions and contrain-
dications. Also, the deliberate decision of the patient not
to take a particular drug must be respected.
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